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Abstract
The feasibility of using complexes with cyclodextrins (CDs) in nicardipine (NC) controlled delivery has been examined,
with a view to extending the pharmaceutical applications spectrum of these carriers. For a fast release fraction, a hydrophilic
b-cyclodextrin derivative (hydroxypropyl-b-cyclodextrin) was employed to form a water-soluble complex. For the sustained-
releasing portion, triacetyl-b-cyclodextrin (TAbCD) was used to provide complexes with appropriate hydrophobicity. An
optimal formulation was designed by the combination of each fraction in different mixing ratios. The release behaviour of
the complexes, as well as of their mixtures, was examined in simulated gastric (pH 1.2) and intestinal (pH 6.8) fluids. The
formulations released the drug rapidly at the initial stage, followed by a slow release. The drug release rate was markedly
retarded in the increasing order of the amount of NC/TAbCD complex. When NC was administered to rabbits, its absorption
was very rapid with a short elimination half-life, while a prolonged maintenance of the plasma levels was obtained for the
two selected formulations. The drug bioavailability was considerably improved especially after the administration of the
mixture of hydrophilic and hydrophobic complexes, when compared with the NC/TAbCD complex. The results suggested
that the critical combination of hydrophilic and hydrophobic CDs complexes, in appropriate ratios, could be a promising
drug delivery system with a prolonged therapeutic effect coupled with a more balanced bioavailability.
  2002 Elsevier Science B.V. All rights reserved.
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1 . Introduction activity and control the drug release at the desired
level, many drug carrier materials, such cyclodex-
In an attempt to optimise the efficacy of drug trins (CDs) have been rationally designed and im-
proved. CDs, cyclic oligosaccharides with a hydro-
phobic central cavity that provides a microenviron-
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physical, chemical and biological properties of sever- frequency of daily administration [13,14]. The in-
al drug molecules, due to their characteristic inclu- corporation of a rapid-dissolving fraction together
sion ability [1–3]. In recent years, various kinds of with a slow-release portion could be advantageous,
chemically-derived CDs have been prepared to ex- since the initial release of a certain amount of NC
tend the physicochemical and inclusion properties will give more balanced oral bioavailability, reduc-
and also the multi-functional pharmaceutical charac- ing the first-pass metabolism in the liver.
teristics of the parent host molecules, their hydroxyl In the present study, the release behaviour of
groups being available as starting points for structur- NC/HPbCD and NC/TAbCD complexes, as well
al modification, without eliminating the central cavi- the corresponding mixtures in different molar ratios,
ty for guest accommodation [3]. Among the chemi- was evaluated in acidic (pH 1.2) and alkaline (pH
cally modified CDs, the hydrophilic CD derivatives, 6.8) media. Furthermore, we have investigated the
such as hydroxypropyl-b-CD (HPbCD) and sul- oral bioavailability of the selected formulations in
fobutyl ether-bCD, are useful to improve the solu- rabbits.
bility, dissolution rate and bioavailability of poorly
water-soluble drugs [4–6], while hydrophobic CD
derivatives, such as ethylated and acylated CDs, have 2 . Material and methods
potential as sustained-release carriers of drugs with
short half-lives [7–9]. Furthermore, advanced con- 2 .1. Materials
trolled release can be achieved by a pertinent hybrid-
ising of complexes obtained with hydrophilic and NC, HPbCD (Kleptose HPB , MW|1300, DS
hydrophobic CD derivatives. 0.63) and TAbCD were purchased from Effechem
We have recently reported [10] that HPbCD is SRL (Italy), Roquette (France) and Sigma–Aldrich
particularly useful to improve the low solubility and (Germany), respectively. All other chemicals and
dissolution rate of nicardipine (NC) in alkaline solvents were of analytical reagent-grade (Merck and
medium. TAbCD was also successfully used to Sigma–Aldrich) and deionised water (Millipore Elix
achieve inclusion compounds with NC and a sus- 5 system) was used throughout the study.
tained drug release profile was observed from these Since NC is light sensitive, almost all experiments
hydrophobic complexes [11]. This led us to design a were carried out in a darkroom under yellow light
sustained release formulation of NC consisting of a (Philips Powertone SON E27). When this photo-
combination of both types of complexes: the hydro- protection was impossible to achieve, all suspensions
phobic NC/TAbCD complex as the slow-release or samples containing NC were protected from light
portion, to provide an appropriate hydrophobicity, by wrapping the vials with aluminium foil.
and the highly hydrophilic NC/HPbCD complex as
the fast-dissolving fraction. 2 .2. Preparation of inclusion complexes
NC, a calcium channel-blocking agent, is an
effective drug in the management of mild to moder- The 1:1 guest /host inclusion complexes were
ate hypertension, angina pectoris and cerebral dis- prepared by the spray-drying method as previously
ease. It was used as model drug since its bioavail- described [10,11]. Briefly, hydroalcoholic solutions
ability is very limited (15–40%) and like other containing equimolar quantities of NC and HPbCD
dihydropyridine derivatives, its standard formulation or TAbCD were spray-dried (LabPlant SD-05),
undergoes rapid absorption and extensive biotrans- under the following conditions: air flow rate, 50
3formation in the liver, with a short elimination half- m /h; atomising air pressure, 1.0 bar; inlet tempera-
life (about 1 h), which often results in significant ture, 160 8C, outlet temperature, 85 8C and flow rate
fluctuations in plasma concentrations [12]. To attain of the solution, 400 ml /h.
a prolonged therapeutic effect and a reduced inci- Physical mixtures of NC and both CDs, in a 1:1
dence of side-effects, sustained release formulations molar ratio, were also prepared for reference.
of NC have been developed to maintain a suitable The evidence of inclusion complexation between
plasma level for a long period of time with minimal NC and HPbCD or TAbCD and the detailed
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physicochemical characterization of the corre- were immediately separated by centrifugation at
sponding complexes were previously reported 3000 rpm for 10 min and stored at 280 8C until
[10,11]. analysis. Baseline plasma samples obtained prior to
Several combinations of both complexes were NC administration at time 0 served as the blank
prepared by mixing, in different molar ratios (1:1, control for each animal.
1:2; 1:4, 1:6 and 1:10), the corresponding amounts of The drug plasma levels were determined by a
NC/HPbCD and NC/TAbCD complexes, in a glass previously described high performance liquid chro-
mortar. matography (HPLC) method with UV detection [15].
Briefly, the method involved the addition of the
internal standard (nimodipine) to the plasma samples
2 .3. In vitro dissolution studies with subsequent solid phase extraction using C18
cartridges. The HPLC system consisted of a Hewlett
The dissolution profiles of NC from the CDs Packard (Waldbronn, Germany) model 1050 pump,
inclusion complexes, as well from the respective equipped with a HP1050 multiple wavelength UV
mixtures, were collected using a Vankel VK7000 detector operated at 254 nm, an injector with a 20-ml
apparatus, according to the USP rotating basket loop and a HP3396A recording integrator. The

method. The dissolution media consisted of 1000 ml stationary phase was a Licrospher 100 RP-18
of enzyme-free simulated gastric (pH 1.2) and reversed-phase column (250 mm34 mm i.d.; 5 mm
intestinal (pH 6.8) fluids (USPXXIV). The stirring mean particle size, Merck) equipped with a guard
speed was 10062 rpm and the temperature was column similarly packed and maintained at 30 8C. A
maintained at 3760.2 8C. Powdered samples con- mixture of acetonitrile–0.02 M sodium phosphate
taining 30 mg of NC or its equivalent were used. At buffer–methanol (45:40:15) with 0.2% triethylamine
set time intervals for a period of 8 h, the amount of and at pH 6.1, delivered at a flow rate of 1.2 ml /min,
dissolved drug was automatically measured by UV was used as mobile phase.
spectroscopy at 357 nm. Dissolution runs were The method proved to be linear in the range of
carried out six times for all samples. 5–100 ng/ml with a regression coefficient of 0.9993.
The relative standard deviations of intra- and inter-
day analysis for NC in plasma were 3.26–6.52%
2 .4. Bioavailability studies in rabbits (n55) and 4.71–9.38% (n55), respectively. The
differences in the mean value measured from the
The bioavailability studies were carried out using concentration prepared, expressed as percentages (%
male New zealand albino rabbits with an average bias), were only 25.2, 0.4 and 0.8% at NC con-
weight of 4 kg, housed individually in standard cages centrations of 5, 25 and 50 ng/ml, which confirmed
in a room with air, humidity and temperature control the accuracy of the method.
and on a 12-h light, 12-h dark cycle. The animals The pharmacokinetic parameters extracted from
were kept on a standard diet. the plasma data were calculated using noncompar-
At least 12 h prior to drug administration, the tmental analysis (WinNonlin , Version 1.1) and
animals were fasted but had free access to water. NC included the maximum plasma concentration (C ),max
and the two selected formulations were administered the time to reach the maximum plasma concentration
orally to six animals, at a dose of 15 mg/kg, with a (T ), the area under the drug plasma concen-max
wash-out period of 2 weeks between the different tration–time curve up to 24 h post-administration
administrations. The formulations were previously (AUC ), the mean residence time (MRT) and the0-24 h
filled in hard capsules in order to facilitate the oral elimination half-life (T ).1 / 2
administration. The statistical analysis of the pharmacokinetic
Blood samples (1.5 ml) were withdrawn from a parameters was carried out using one-way analysis of
heparinized catheter placed in the marginal vein of variance (ANOVA) with Bonferroni post test for
the ear before administration and at predetermined multiple comparisons. A value of P,0.05 defined
times, using EDTA as anticoagulant. Plasma samples the statistical significance.
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Fig. 1. Dissolution profiles of NC, NC/HPbCD and NC/TAbCD inclusion complexes in simulated gastric fluid (pH 1.2). Data are
presented as mean6S.D., n56.
3 . Results and discussion since NC is a weak basic drug (pK 57.2), thea
amount of dissolved drug in the intestinal fluid was
3 .1. In vitro dissolution studies lower than that observed in the gastric fluid. The
NC/HPbCD complex displayed better dissolution
The dissolution profiles of NC and of the NC/CDs properties with respect to NC alone, being immedi-
spray-dried inclusion complexes in simulated gastric ately dispersed and completely dissolved within 15
fluid (pH 1.2) and simulated intestinal fluid (pH 6.8) min. The improvement of NC dissolution charac-
are presented in Figs. 1 and 2, respectively. The teristics upon complexation with HPbCD was more
dissolution of the plain drug, in the acidic medium, evident in the simulated intestinal fluid, which is in
was completed only within ca. 3 h. As expected, accordance with the higher stability constants for the
Fig. 2. Dissolution profiles of NC, NC/HPbCD and NC/TAbCD inclusion complexes in simulated intestinal fluid (pH 6.8). Data are
presented as mean6S.D., n56.
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complexation between NC and this CD in alkaline effects. However, in the slow-release-type prepara-
media, as previously reported [10]. The significant tions there is usually a lag time for reaching an
enhancement of the low dissolution properties of NC effective blood level of drug. For this reason, an
from the NC/HPbCD spray-dried complex has been initial rapid release would be necessary to avoid this
attributed to: (1) surfactant-like properties of the lag time and offer a more balanced bioavailability.
carrier, which can reduce the interfacial tension To gain a rapid appearance of NC in the blood and to
between water-insoluble drugs and the dissolution maintain a constant drug level for a long period of
medium; (2) an increase in NC solubility upon time, we decided to hybridise a fast-releasing frac-
complexation in the solid state; (3) the high ener- tion with the slow-releasing NC/TAbCD complex.
getic amorphous state following complexation, as Because of the poor aqueous solubility and wettabili-
confirmed by previous X-ray diffractometry studies ty of NC, we employed the highly water-soluble
[5,16,17]. NC/HPbCD complex as the immediate-release com-
On the other hand, it was clearly observed that the pound, in the expectation of an enhanced initial
dissolution rate of NC, in both dissolution media, release rate of NC.
was markedly retarded by complexation with the Thus, in the next step, an optimisation of the
hydrophobic TAbCD, mainly due to the poor water release profile of NC was attempted by the combina-
solubility of this complex. Indeed, a total release of tion of the HPbCD and TAbCD spray-dried com-
NC at pH 1.2 was observed after ca. 3 h from the plexes, in different molar ratios (1:1, 1:2, 1:4, 1:6
plain drug, whereas this state was not reached after 8 and 1:10). The effect of the varying molar ratios on
h from the NC/TAbCD spray-dried complex. The the release behaviour of the formulations composed
complex formation with TAbCD also resulted in a of NC/HPbCD and NC/TAbCD spray-dried com-
significant reduction in the release rate of NC in the plexes in the simulated gastric (pH 1.2) and simu-
simulated intestinal fluid: a ca. 25% drug release lated intestinal fluid (pH 6.8) is shown in Figs. 3 and
percentage from this hydrophobic complex was only 4, respectively.
achieved after 8 h. The release patterns from the different formula-
NC should be released according to zero-order tions reflected that of each component, i.e. the NC
kinetics for a long period of time, because of such corresponding to the fast-releasing fraction was
therapeutic advantages as the duration of its pharma- rapidly released, and then the residual amount of
cological effect and the lowering of the drug side- drug was gradually released from the slow-releasing
Fig. 3. Dissolution profiles of (NC/HPbCD complex) /(NC/TAbCD complex) in different molar ratios in simulated gastric fluid (pH 1.2).
Data are presented as mean6S.D., n56.
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Fig. 4. Dissolution profiles of (NC/HPbCD complex) /(NC/TAbCD complex) in different molar ratios in simulated intestinal fluid (pH
6.8). Data are presented as mean6S.D., n56.
fraction, according to zero-order kinetics. Indeed, the 3 .2. Bioavailability studies in rabbits
drug release occurred in two stages: faster release in
the initial stage (up to 1 h) and slower release in the The mean plasma concentrations of NC following
second stage. Compared to NC alone, the drug a single oral dose of the plain drug, formulation I
release rate from all these formulations was sig- (mixture of HPbCD and TAbCD complexes in a
nificantly suppressed, a result of the retarding effect molar ratio of 1:4) or formulation II (TAbCD
of the hydrophobic complex in the mixture. In complex), equivalent to 15 mg/kg, are shown in Fig.
contrast, the increase in the initial dissolution rate 5. The pharmacokinetic parameters calculated for the
appeared to be proportional to the molar ratio of the six animals are summarized in Table 1.
fast-dissolving faction, i.e. NC/HPbCD complex, in
the formulations (1:10,1:6,1:4,1:2,1:1).
It was evident from these results that the NC
release rate could be critically modified by changing
the mixing ratio of the hydrophilic and hydrophobic
CD inclusion complexes.
From inspection of the dissolution profiles, among
the various combinations, the 1:4 mixture of both
complexes, namely formulation I, seemed to be
suitable for our purpose with regard to the release
pattern and release time. This formulation provided a
sufficiently slow release of the drug for a long period
of time following an initial rapid dissolution (about
40% drug release at stomach pH). A sufficient
release of drug in the early stage would be necessary
Fig. 5. NC plasma concentration–time profiles after oral adminis-to offer a more balanced bioavailability because the
tration of NC, 1:4 mixture of NC/HPbCD and TAbCD complex-
stomach is an important absorption site. We also
es (formulation I) and NC/TAbCD complex (formulation II), at a
selected the NC/TAbCD complex (formulation II) dose of 15 mg/kg, to rabbits. Each point represents the
for further in vivo studies. mean6S.E., n56.
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Table 1
Pharmacokinetic parameters of NC after oral administration of plain NC, 1:4 mixture of NC/HPbCD and TAbCD complexes (formulation
I) and NC/TAbCD complex (formulation II), at a dose of 15 mg/kg, to rabbits (n56)
C T AUC MRT Tmax max 0-24 h 1 / 2
(ng /ml) (h) (ng h/ml) (h) (h)
NC 69.6468.57 1 129.1069.44 1.6060.14 1.6060.38
Formulation I 39.6561.11 3 411.8467.23 5.4160.02 5.4960.17
Formulation II 18.2560.74 4 202.8269.07 5.5560.11 7.3861.61
Each value represents the mean6S.E., with the exception of the T parameter, which is represented by the median.max
The absorption of NC in rabbits was very rapid for II, which could explain the sparing increase in the
the plain drug, with a time to reach the maximum AUC of the later. This behaviour was probably0-24 h
plasma level (69.64 ng/ml) of 1 h. This drug showed due to the extremely slow dissolution rate of the
a short elimination half-life (1.60 h), reflecting its NC/TAbCD complex.
rapid disappearance in the plasma of the animals and From the inspection of these results, we could
the concentration could not be detected after 8 h, verify that the in vitro release behaviours were
being below the minimum detection limit of 5 ng/ partially reflected in the plasma levels after the
ml. The plasma concentrations of NC after oral administration of the corresponding formulations.
administration of both formulations did not show a For example, NC gave an initial rapid increase in
sharp peak and the corresponding times to reach the plasma drug levels, followed by a rapid decrease.
maximum plasma level were significantly prolonged, The sustained plasma levels of the drug observed for
3 and 4 h for formulations I and II, respectively. a long period when formulations I and II were
Also, the plasma concentrations were maintained at a administered reflected their slow in vitro release
relatively constant level for a long period when the pattern. Formulation I gave an initial rapid increase
drug was administered as the two formulations, in the drug plasma level, followed by its mainte-
presenting a somewhat sustained-release pattern. nance at a relatively constant level, which could be
However, the plateau obtained in the drug plasma well correlated with the two stages of the in vitro
concentrations was more evident after the adminis- drug release mentioned above. Compared to the
tration of formulation II. In addition, the MRT values hydrophobic complex alone, formulation I produced
displayed by formulations I and II were about 3.5- a faster initial increase in the NC plasma level,
fold larger than that of NC alone, confirming the which could reflect the presence of the hydrophilic
sustained-release behaviour of these preparations in complex, in a perfect correlation with the in vitro
the rabbit model. However, no significant difference release profiles.
in the MRT values was observed between the two The attenuation of the initial high peak of the drug
formulations. plasma concentrations, after the administration of the
It was interesting to note that there was a 3.2- and selected formulations, suggested that the frequency
1.6-fold increase in the AUC value for formula- and severity of NC side-effects could also be re-0-24 h
tions I and II, respectively, corresponding to a duced. Further, the formulation constituted by the
greater extent of oral absorption when compared combination of HPbCD and TAbCD complexes
with the drug alone. This increase in the AUC produced retarding effects with superior oral bio-0-24 h
may be due to a longer residence time of these availability compared with NC and the hydrophobic
formulations in the gastrointestinal tract, as was TAbCD complex alone.
suggested by their larger MRT and T values. Themax
difference in the AUC between formulations I0-24 h
and II was also found to be statistically significant 4 . Conclusions
(P,0.05). The drug plasma levels in the initial stage
after the administration of formulation I were mark- The NC release rate could be controlled by
edly higher than the levels obtained for formulation adjusting the mixing ratio of its hydrophilic
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